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The mammalian target of rapamycin (mTOR)
promotes anabolic cellular processes in response
to growth factors and metabolic cues. The TSC1
and TSC2 tumor suppressors are major upstream
inhibitory regulators of mTOR signaling. Mice with
Rip2/Cre-mediated deletion of Tsc1 (Rip-Tsc1cKO
mice) developed hyperphagia and obesity, suggest-
ing that hypothalamic disruption (for which Rip2/Cre
is well known) of Tsc1 may dysregulate feeding
circuits via mTOR activation. Indeed, Rip-Tsc1cKO
mice displayed increased mTOR signaling and
enlargedneuroncell size in a number of hypothalamic
populations, including Pomc neurons. Furthermore,
Tsc1 deletion with Pomc/Cre (Pomc-Tsc1cKO mice)
resulted indysregulationofPomcneuronsandhyper-
phagic obesity. Treatment with the mTOR inhibitor,
rapamycin, ameliorated the hyperphagia, obesity,
and the altered Pomc neuronal morphology in devel-
oping or adult Pomc-Tsc1cKO mice, and cessation
of treatment reinstated these phenotypes. Thus,
ongoing mTOR activation in Pomc neurons blocks
the catabolic function of these neurons to promote
nutrient intake and increased adiposity.
INTRODUCTION
The mammalian target of rapamycin (mTOR), an evolutionarily
conserved serine-threonine kinase, promotes anabolic cellular
processes such as protein synthesis in response to growth
factors, nutrients (amino acids and glucose), and stress (Biondi
et al., 2004; Wullschleger et al., 2006). mTOR exists in two distinct
complexes, mTORC1 and mTORC2. TSC1 and TSC2 are tumor
suppressors, and their gene products form a stable complex.362 Cell Metabolism 9, 362–374, April 8, 2009 ª2009 Elsevier Inc.The major function of TSC1/TSC2 tumor suppressors is to inhibit
mTORC1 (Inoki et al., 2005), and mutation in either TSC1 or TSC2
leads to constitutive activation of mTORC1; in patients, this
results in multiorgan hamartomas. The TSC1/TSC2 dimer has
GTPase-activating protein (GAP) activity specifically toward the
Rheb GTPase, which directly binds and activates TORC1 but
not TORC2 (Long et al., 2005; Sancak et al., 2007; Yang et al.,
2006). Furthermore, amino acids and cellular energy levels stim-
ulate TORC1, but not TORC2. For the purposes of this report,
subsequent statements about mTOR refer to TORC1.
Within the TSC1/2 complex, the TSC1 subunit stabilizes and
regulates the GAP activity of TSC2, which inactivates Rheb.
During insulin signaling, the PI3K-Akt pathway activates mTOR
by phosphorylating and thereby inhibiting TSC2 (Inoki et al.,
2002; Manning et al., 2002; Nguyen et al., 2006); the Akt-depen-
dent phosphorylation of PRAS40 may also contribute to mTOR
activation (Oshiro et al., 2007; Sancak et al., 2007; Vander
Haar et al., 2007; Wang et al., 2007). Energy limitation, such as
glucose deprivation, strongly inhibits mTOR, and the glucose
deprivation-induced mTOR inhibition is compromised in TSC
mutant cells. AMPK, a cellular energy sensor, directly phosphor-
ylates TSC2 to inhibit mTOR. AMPK can also inhibit mTORC1 by
phosphorylating Raptor, an essential mTOR1 subunit. Thus, the
TSC1/2 complex integrates multiple upstream signals to modu-
late mTOR activity (Gao et al., 2002; Inoki et al., 2002, 2003;
Manning et al., 2002; Wullschleger et al., 2006).
Although the PI3K-Akt cascade regulates many cellular
processes by phosphorylating numerous substrates, including
FOXO and AS160, and plays an important role in the hypotha-
lamic control of feeding (Belgardt et al., 2008; Brunet et al.,
1999; Kitamura et al., 2006; Kops et al., 1999; Plum et al., 2006;
Sano et al., 2003), the function of mTOR activation for appetite
regulation by the CNS has not been thoroughly investigated.
Recent findings have suggested a potential role for mTOR as
a cellular fuel sensor in hypothalamic circuits that regulate energy
balance, especially in orexigenic agouti-related peptide (AgRP)-
expressing neurons, where feeding status prominently regulates
mTOR activity (Cota et al., 2006). Increased hypothalamic
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Anabolic Action of mTOR in Pomc Neuronsavailability of leucine stimulates mTOR activity and reduces food
intake in an mTOR-dependent manner. Hypothalamic mTOR
activity is also required for the suppression of feeding by leptin.
Thus, mTOR contributes to acute sensing of the nutritional milieu
in the regulation of feeding by hypothalamic neural circuits. In
contrast, the hyperactivation of mTOR in peripheral metabolic
tissues, such as muscle and liver, during nutritional excess in
high-calorie feeding and obesity also contributes to insulin resis-
tance and metabolic dysfunction (Korsheninnikova et al., 2006;
Miller et al., 2008). Such chronic activation of mTOR could simi-
larly dysregulate the energy-sensing hypothalamic neurons that
control feeding and perturb whole-body energy balance.
We generated a mouse line conditionally lacking Tsc1 in both
pancreatic b cells and hypothalamic neurons (Rip-Tsc1cKO
mice) using Rip2/Cre and another line lacking Tsc1 specifically
in Pomc neurons (Pomc-Tsc1cKO) using Pomc/Cre. Our studies
demonstrate hyperphagic obesity in both the Rip-Tsc1cKO and
Pomc-Tsc1cKO mice due to uncontrolled chronic activation of
mTOR in both Rip neurons and Pomc neurons. These results
suggest that the TSC-mTOR pathway plays crucial roles in the
function of appetite-suppressing neural circuits; dysregulated
activation of the mTOR pathway in the CNS might be a potential
mechanism leading to the development of obesity.
RESULTS
Hyperphagic Obesity in Rip-Tsc1cKO Mice
To study the in vivo function of mTOR activation in metabolism,
we set out to analyze mice lacking Tsc1, a major upstream inhib-
itor of mTOR. Since conventional knockout of Tsc1 leads to
embryonic lethality (Kobayashi et al., 2001; Kwiatkowski et al.,
2002; Murakami et al., 2004), we generated a loxP-flanked floxed
Tsc1 allele (Tsc1lox) to permit tissue-specific Tsc1 knockout.
Tsc1lox/lox homozygotes (Meikle et al., 2005; Uhlmann et al.,
2002) were mated with the Cre transgenic line driven by Rip2
(Choudhury et al., 2005; Kubota et al., 2004; Lin et al., 2004;
Nguyen et al., 2006; Stiles et al., 2006). All subsequent experi-
ments were performed using Rip-Cre/Tsc1lox/lox (Rip-Tsc1cKO)
mice and littermate Tsc1lox/lox (also known as control/WT)
mice. Western blotting confirmed markedly reduced Tsc1
expression in isolated islets from Rip-Tsc1cKO mice (data not
shown). As expected, Tsc1 deletion mediated by Rip/Cre results
in increased mTOR activity in b cells along with increased b cell
size and islet mass and higher insulin content and secretion (our
unpublished data).
Interestingly, in addition to their b cell phenotype, Rip-
Tsc1cKO male mice displayed increased body weight compared
with controls by 6 weeks of age (Figure 1A). By 12 weeks of age,
Rip-Tsc1cKO mice were 36% heavier than control animals. The
body weight of the Rip-Tsc1cKO female mice was also signifi-
cantly higher than that of the controls (data not shown). Further-
more, 24-week-old Rip-Tsc1cKO mice displayed increased
whole-body fat content and increased adipocyte cell size
compared with that of WT mice (Figures 1B and 1C). No differ-
ence in length was observed between the two genotypes
(Figure S1A). Consistent with the increased adiposity of Rip-
Tsc1cKO mice, serum leptin levels were significantly elevated
relative to controls in both fasted and fed states in Rip-Tsc1cKO
mice at 4 weeks of age, at which the Rip-Tsc1cKO mice havenormal body weight (Figure 1D). To examine leptin action in
Rip-Tsc1cKO mice, we assessed the effect of administering lep-
tin peripherally for 2 days. This treatment markedly reduced food
intake and body weight in control animals (Figures 1E and 1F). In
contrast, leptin had little effect on food intake in the Rip-
Tsc1cKO mice, suggesting impairment of the leptin-regulated
neural satiety circuits in these Rip-Tsc1cKO mice.
In order to understand the basis for this increased adiposity,
we examined food intake from 4 to 6 weeks of age, when the
difference in body weight between the two genotypes began to
appear. We found that food consumption by Rip-Tsc1cKO
mice was greater than that of the control animals (Figure 1G),
suggesting that the obese phenotype in Rip-Tsc1cKO mice
results from increased food intake. Consistently, pair-fed Rip-
Tsc1cKO mice displayed similar body weights compared to
WT mice (Figure 1H). Thus, Rip-Tsc1cKO mice develop hyper-
phagic obesity, suggesting an important role for mTOR in the
regulation of food intake and body weight.
Hypothalamic Tsc1 Deletion in Rip-Tsc1cKO Mice
Rip-Cre mice express Cre in the hypothalamus during develop-
ment, resulting in the excision of floxed genes in a diverse set
of hypothalamic neurons (Choudhury et al., 2005; Kubota et al.,
2004; Lin et al., 2004; Nguyen et al., 2006; Stiles et al., 2006).
Although immunoblotting revealed no detectable alteration in
Tsc1 protein levels in the whole brain of Rip-Tsc1cKO mice
(Figure S1B), analysis of the dissected hypothalamus demon-
strated reduced Tsc1 protein levels, supporting Cre-mediated
deletion of Tsc1 in the hypothalamus of these animals
(Figure 2A). Tsc2 expression was also decreased when Tsc1
was deleted (Figure 2A), consistent with the proposed role for
Tsc1 in stabilizing Tsc2 (Chong-Kopera et al., 2006; Meikle
et al., 2007). We determined the activation status of mTOR by
immunoblotting for phosphorylated S6 (pS6). The mTOR-depen-
dent activation of S6K results in S6 phosphorylation, which thus
serves as a convenient readout for mTOR activity (Flotow and
Thomas, 1992; Pende et al., 2004). Immunoblotting revealed
markedly increased pS6 levels in the hypothalamus of Rip-
Tsc1cKO mice (Figure 2A). Immunofluorescence analysis
confirmed elevated pS6-immunoreactivity (pS6-IR) in many
neurons in a number of hypothalamic nuclei important for energy
homeostasis (including the arcuate nucleus [ARC], ventromedial
hypothalamic nucleus [VMH], and dorsomedial hypothalamic
nucleus [DMH]), indicating that mTOR was activated in the hypo-
thalamus of these animals (Figures 2B and S2). To test the mTOR
dependence of the increased pS6 in Rip-Tsc1cKO hypothalami,
we treated the mice with rapamycin, a specific mTOR inhibitor.
While not restored by the peripheral administration of 1 mg/kg
rapamycin (which ameliorated the effects of Tsc1 deletion in
the b cell [our unpublished data]), higher (6 mg/kg) doses of rapa-
mycin normalized pS6-IR inRip-Tsc1cKO hypothalami, revealing
the mTOR dependency of the hypothalamic pS6 (Figure 2B).
Dysregulation of the Melanocortin System
in Rip-Tsc1cKO Mice
The Rip-Tsc1cKO mice display high leptin levels and hyper-
phagia (Figures 1D and 1G). The inability of elevated leptin levels
to mitigate hyperphagia in Rip-Tsc1cKO mice suggests the
potential dysfunction of the neural systems that regulate bodyCell Metabolism 9, 362–374, April 8, 2009 ª2009 Elsevier Inc. 363
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Anabolic Action of mTOR in Pomc Neuronsenergy homeostasis in response to leptin in these animals.
Quantitative real-time PCR (qPCR) analysis demonstrated that
leptin receptor (Lepr) mRNA levels were increased in Rip-
Tsc1cKO hypothalami (Figure S3), however, suggesting that
the obesity of the Rip-Tsc1cKO animals was not due to attenu-
ated Lepr expression. In order to identify potential contributing
Figure 1. Hyperphagic Obesity in Rip-Tsc1cKO Mice
(A) Obesity in Rip-Tsc1cKO mice; body weight in male litter-
mates fed on regular chow diet from 4 to 24 weeks of age
(n = 17–22).
(B) Increased adipocyte size in Rip-Tsc1cKO mice; H&E stain-
ing of epididymal fat depots from Rip-Tsc1cKO and control
mice at 24 weeks of age.
(C) Increase of fat content in Rip-Tsc1cKO mice. Fat content
was measured using a dual energy X-ray absorptiometry
(DEXA) scanner (n = 6–7).
(D) Hyperleptinemia inRip-Tsc1cKOmice; serum leptin levels in
16 hr fasted or ad lib-fed male mice at 4 weeks of age (n = 6–8).
(E and F) Impaired response to leptin in Rip-Tsc1cKO mice.
Male mice at 4–5 weeks of age were injected i.p. with leptin
(2.5 mg/kg body weight) twice daily (at 9:30 and 18:30) for
2 days (n = 6). Food intake was measured each day, and
changes in food intake are reported relative to baseline intake
(E). Body weight was measured every day, and changes are
reported relative to initial body weight (F).
(G) Rip-Tsc1cKO mice are hyperphagic. Food intake in
4-week-old male mice over a 2 week period (n = 7–8).
(H) Body weight of 8-week-old pair-fed male mice. Rip-
Tsc1cKO and WT mice were given the average amount of
foodconsumed by age-matched control mice from 4 to8 weeks
of age (n = 7).For (A)–(H),Rip-cKOorR-cKO:Rip-Tsc1cKO; WT:
control. Values are mean ± SEM. *p < 0.05, **p < 0.001.
mechanisms underlying the altered feeding and
energy balance of the Rip-Tsc1cKO mice, we
examined mRNA expression of hypothalamic
appetite-controlling neuropeptides that are known
to be regulated by leptin (Coll et al., 2007; Flier,
2004). ARC neurons release orexigenic peptides
such as neuropeptide Y (NPY) and AgRP and
anorexigenic peptides such as those derived from
POMC. Pomc and Npy mRNA levels were dysregu-
lated in ad libitum-fedRip-Tsc1cKO mice, and fast-
ing failed to decrease Npy mRNA levels in these
mice;AgrpmRNA levels were normal and remained
responsive to fasting in these animals (Figure 2C).
Both increased Npy and decreased Pomc expres-
sion would predict increased feeding in the Rip-
Tsc1cKO mice. The appropriate control of Agrp
expression in the same neurons that display dysre-
gulated Npy expression is consistent with previous
findings demonstrating that the expression of Npy
and Agrp are controlled by distinct upstream
signals (Bates et al., 2003; Kitamura et al., 2006),
and it suggests an important role for hypothalamic
mTOR in the regulation of Npy, but not Agrp.
The dysregulation of neuropeptide expression in
multiple populations of ARC neurons is consistent
with Rip2/Cre-mediated deletion in multiple popu-
lations of hypothalamic neurons, including both
anorectic and orexigenic cell types. Other neuronal populations
are likely affected as well, and the anorectic action of the majority
of the neurons in this region of the hypothalamus presumably
results in a net orexigenic response to the dysregulation of
neurons throughout the ARC. These results suggest that uncon-
trolled mTOR activation blunts the physiological regulation of364 Cell Metabolism 9, 362–374, April 8, 2009 ª2009 Elsevier Inc.
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Figure 2. Hypothalamic Tsc1 Deletion and Dysregulation of the Melanocortin System in Rip-Tsc1cKO Mice
(A) Tsc1 and Tsc2 protein levels decrease inRip-Tsc1cKO hypothalamus. Upper panel shows immunoblot analysis of Tsc1, Tsc2, p-S6, S6, and a a-tubulin in the
hypothalamus. Hypothalamic extracts were prepared from individual animals. Lower panel shows amount of Tsc1 normalized to total a-tubulin (n = 12).
(B) Elevated pS6-IR inRip-Tsc1cKO hypothalamus. Hypothalamic sections from ad lib-fedRip-Tsc1cKO and control mice at 4 weeks of age were stained with p-S6
(Ser235/236) antibody. For rapamycin treatment, 2-week-old Rip-Tsc1cKO mice were injected with rapamycin (1mg/kg body weight) or high dose rapamycin
(6mg/kg body weight), as indicated, every other day for 2 weeks. Hypothalami were harvested 12 hr after the last treatment of rapamycin. ME: median eminence.
(C) Altered expression of hypothalamic peptides in Rip-Tsc1cKO mice. Pomc, Npy, and Agrp mRNA levels in the hypothalamus were measured by real-time
RT-PCR in 4-week-old Rip-Tsc1cKO and control mice under 24 hr fasting and ad lib feeding conditions. Values normalized to Hprt mRNA are expressed relative
to fasted control mice. For (A) and (C), data are expressed as the average ± SEM, *p < 0.05, **p < 0.01. For all panels, Rip-cKO: Rip-Tsc1cKO; WT: control.Pomc and Npy, and that dysregulation of anorexigenic neurons,
such as the Pomc cells, may contribute to the hyperphagic
obesity of the Rip-Tsc1cKO mice.
We examined the somatic size and projections of the anorex-
igenic Pomc neurons by immunohistochemical analysis of
ACTH, a neuropeptide derived from POMC. Visual inspection
suggested the marked hypertrophy of ACTH-IR neuronal soma
in the ARC of the hypothalamus (Figure 3A) along with the dimi-
nution of ACTH-IR neuronal projections to the paraventricular
nucleus (PVN) in Rip-Tsc1cKO mice compared to controls
(Figure 3B). Thus, ablation of Tsc1 by Rip2/Cre likely impairs
signaling by Pomc neurons. In order to examine the mTOR
dependence of these effects, we treated animals with rapamycin
for 2 weeks (from 2 to 4 weeks of age), using the dose (6 mg/kg,
i.p.) that we had previously found effective in attenuating theincreased hypothalamic mTOR activity in Rip-Tsc1cKO mice
(Figure 2B). As shown in Figure 3A, this treatment largely cor-
rected the obvious morphological alterations of ACTH-IR cells
in the Rip-Tsc1cKO mice, as well as increasing the density of
ACTH-IR projections to the PVN in Rip-Tsc1cKO mice
(Figure 3B). Consistent with these histologic improvements, the
body weight phenotype of the rapamycin-treated Rip-Tsc1cKO
mice improved (Figure 3C).
Taken together, these data suggest a crucial role for Tsc1 in
inhibiting mTOR activity and thereby preserving the normal regu-
lation and function of hypothalamic neurons that modulate
energy balance, and they further suggest a potential contribution
of pathologic changes promoted by mTOR activation in the
Pomc neurons of the Rip-Tsc1cKO mice to the hyperphagic
obesity of these animals.Cell Metabolism 9, 362–374, April 8, 2009 ª2009 Elsevier Inc. 365
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Anabolic Action of mTOR in Pomc NeuronsFigure 3. Rapamycin Treatment Normalized the Morphological Alterations of Pomc Neurons in Rip-Tsc1cKO Mice
(A) Rapamycin normalized the morphological alterations of ACTH-IR cells in the Rip-Tsc1cKO arcuate nucleus (ARC). 3V: third ventricle.
(B) Rapamycin normalized the density of ACTH-IR projections to the PVN inRip-Tsc1cKO mice. PVN: paraventricular nucleus (A and B). Representative images of
ACTH-IR in Rip-Tsc1cKO and WT hypothalami are shown. Twenty-four hour fasted or ad lib-fed Rip-Tsc1cKO and control mice were used for this experiment.
Two-week-old Rip-Tsc1cKO and control mice were injected with rapamycin (6 mg/kg body weight) or vehicle (as indicated) every other day for 2 weeks. The
hypothalami were harvested 12 hr after the last treatment of rapamycin.
(C) Rapamycin normalized the body weight of Rip-Tsc1cKO mice. Body weight of 6-week-old female littermates fed on regular chow diet were compared to
animals in which 2-week-old Rip-Tsc1cKO and control mice were injected with rapamycin (6 mg/kg body weight) every other day until 6 weeks of age. Data
are expressed as the average ± SEM, **p < 0.01.
For (A)–(C), Rip-cKO: Rip-Tsc1cKO; WT: control.366 Cell Metabolism 9, 362–374, April 8, 2009 ª2009 Elsevier Inc.
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Figure 4. Dysregulation of Hypothalamic Pomc Neurons
in Pomc-Tsc1cKO Mice
(A) Representative p-S6 (Ser235/236) staining of hypothalamus from
4-week-old Pomc-Tsc1cKO and control mice fasted 24 hr or ad libitum fed.
Pomc-Tsc1cKO mice show increased pS6-IR in the ARC.
(B and C) Loss of ACTH projections to PVN and increased cell size in Pomc-
Tsc1cKO mice; immunohistochemistry for ACTH in hypothalamus of adAltered Pomc Neurons in Pomc-Tsc1cKO Mice
While the excision of conditional alleles in the hypothalamus by
the Rip2/Cre transgene is well established, the neurons affected
by this excision are diverse and poorly characterized, rendering
it difficult to pinpoint a single neuronal mechanism underlying
the obesity ofRip-Tsc1cKO mice. The alterations observed within
the Pomc neurons of the Rip-Tsc1cKO mice suggest that these
neurons represent one affected population, and that mTOR acti-
vation in the Pomc neurons might contribute to the hyperphagic
obesity of the Rip-Tsc1cKO mice, however. We thus generated
mice harboring a conditional disruption of Tsc1 specifically in
Pomc neurons (Pomc-Tsc1cKO mice). The hypothalami of these
Pomc-Tsc1cKO animals displayed elevated pS6-IR independent
of nutritional status in a discrete set of enlarged ARC neurons
(Figure 4A). While the rapid export of neuropeptides from the
neural soma in mice prevents the detection of all Pomc neurons
by ACTH-IR, the number of ACTH-IR neurons did not differ
between Pomc-Tsc1cKO and control animals (Figures 4B and
4D, left graph). The ACTH-IR Pomc soma colocalized with the
pS6-IR neurons in the Pomc-Tsc1cKO animals, and the size
of the ACTH-IR neurons was significantly increased in the
Pomc-Tsc1cKO animals, consistent with the known specificity
of Pomc/Cre for these neurons as well as the increased mTOR
activity that accompanies the deletion of Tsc1 (Figures 4B and
4D). The Pomc-Tsc1cKO mice also displayed decreased ACTH-
IR axonal projections to the PVN (Figures 4C and 4D, right graph)
compared to control mice. Both the colocalization of strong pS6-
IR in ACTH-IRneurons and the shift in the sizeof all ACTH-IRsoma
in the Pomc-Tsc1cKO mice (Figure S4A) suggests an efficient
excision of Tsc1 in these animals. Thus, mTOR activation cell-
autonomously promotes hypertrophy in Pomc soma and
abnormal ATCH-IR neuronal projections inPomc-Tsc1cKO mice.
Hyperphagic Obesity in Pomc-Tsc1cKO Mice
We found that Pomc-Tsc1cKO mice weighed significantly more
than control mice by 6 weeks of age (Figure 5A), and this increase
in body weight reflected increased adiposity, as demonstrated by
their increased fat pad mass and circulating leptin levels (Figures
5B, 5C, and S4C). To directly examine leptin action in Pomc-
Tsc1cKO mice, we assessed the effect of administering leptin
peripherally for 2 days. Though leptin treatment markedly
reduced food intake and body weight in control animals, this
effect was significantly attenuated in the Pomc-Tsc1cKO mice
(Figures 5D and 5E). Furthermore, Pomc-Tsc1cKO mice
consumed more food than controls during the period of highly
divergent weight gain from 6 to 8 weeks of age (Figure 5F).
These changes were not attributable to alterations in the HPA
lib-fed, 7-week-old Pomc-Tsc1cKO and control mice. Detection of ACTH-IR
Pomc neurons (red; upper panel), pS6-IR neurons (green; middle), and their
colocalization (lower) in Pomc-Tsc1cKO and control animals are shown (B).
Arrows are double-labeled neurons. Representative sections of ACTH projec-
tions to the PVN are also shown (C).
(D) ACTH-IR cell number in ARC, the cell size of the ACTH-IR neurons in ARC,
and relative projection density in the PVN. ACTH-IR cells from within matched
sections were compared with two genotypes as described in the Experimental
Procedures (n > 7 per genotype). For PVN projection density, ACTH-IR levels
were measured in matched sections and are reported relative to control
density. Values are mean ± SEM. **p < 0.01. For (A)–(D), P-cKO or Pomc-
cKO: Pomc-Tsc1cKO; WT: control; 3V: third ventricle.Cell Metabolism 9, 362–374, April 8, 2009 ª2009 Elsevier Inc. 367
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Anabolic Action of mTOR in Pomc NeuronsFigure 5. Hyperphagic Obesity in Pomc-Tsc1cKO Mice
(A) Obesity in Pomc-Tsc1cKO mice; body weight in male littermates fed on regular chow diet from 4 to 24 weeks of age (KO: n = 12, WT: n = 8).
(B) Increased fat pad in Pomc-Tsc1cKO mice; weight (percentage of body weight) of intra-abdominal fat pad from 8-week-old male mice (n = 7, male).
(C) Hyperleptinemia in Pomc-Tsc1cKO mice. Serum leptin levels were measured in 24 hr fasted or ad lib-fed 4-week-old male mice (n = 6–8).
(D and E) Decreased response to leptin in Pomc-Tsc1cKO mice. Mice (4–5 months of age) were injected i.p. with leptin (2.5 mg/kg body weight) twice daily (at
09:30 and 18:30) for 2 days (n = 6). Changes in food intake are reported relative to baseline intake (D). Body weight was measured every day, and changes are
reported relative to initial body weight (E).
(F) Food intake in male mice over the indicated 2 week periods (n = 7). Pomc-Tsc1cKO mice are hyperphagic. For (A)–(F), P-cKO or Pomc-cKO: Pomc-Tsc1cKO;
WT: control. Values are mean ± SEM. *p < 0.05, **p < 0.01.(hypothalamic-pituitary-adrenal) axis, ascirculatingcorticosterone
levels were similar in control and Pomc-Tsc1cKO animals at 4 and
24 weeks of age (Figure S4B). These data indicate that Tsc1 abla-
tion in Pomc neurons alone induced hyperphagic obesity. Taken
together, our results suggest that TSC-mTOR signals in Pomc
neurons play a crucial role in the physiology of these neurons
and in the regulation of energy homeostasis, and that anabolic
mTOR signaling in the Pomc neurons attenuates the catabolic
function of these neurons to promote energy uptake and storage.
Rapamycin Treatment of Pomc-Tsc1cKO Mice
In order to examine roles for altered development and ongoing
mTOR activity in the phenotypes of the Pomc-Tsc1cKO animals,
we chronically treated two groups of animals with centrally effec-
tive doses of rapamycin (6 mg/kg, i.p.) (Figure 3B) or vehicle
(Figures 6A and S5A). In the first group (Treatment A), 2-week-
old Pomc-Tsc1cKO and WT mice were treated with rapamycin
for 5 weeks (from 2 to 7 weeks of age) and then switched to
vehicle treatment for an additional 5 weeks (from 7 to 12 weeks
of age). Conversely, for Treatment B, the animals were treated
with vehicle for the initial 5 weeks and then switched to rapamycin
treatment for the second 5 week period. For each treatment368 Cell Metabolism 9, 362–374, April 8, 2009 ª2009 Elsevier Inc.group, some animals were sacrificed at 7 or 12 weeks of age
for the analysis of fat pads and hypothalamic histology. We exam-
ined average food intake from 4 to 7 weeks of age and again after
the switch in treatment from 7 to 12 weeks of age.
The body weight of Pomc-Tsc1cKO male mice was similar to
controls during the rapamycin treatment period from 2 to 7 weeks
of age in Treatment A, but thePomc-Tsc1cKO mice gained signif-
icantly more weight following the switch to vehicle treatment after
7 weeks of age (Figure 6B, upper). The adiposity (measured by fat
pad weight), leptin levels, and food intake for thePomc-Tsc1cKO
mice was also similar to controls throughout the initial rapamycin
treatment phase of these animals but increased, along with body
weight, following the switch to vehicle in Treatment A (Figures
6C–6E). Thus, while rapamycin treatment from 2 to 7 weeks of
age normalizes metabolic parameters in Pomc-Tsc1cKO mice,
these improvements are lost upon discontinuation of rapamycin.
As for untreated animals (Figure 5), the body weight of Pomc-
Tsc1cKO mice increased rapidly compared to controls in the first
(vehicle treatment) phase of Treatment B animals (Figure 6B,
lower); these animals also displayed hyperphagia with increased
fat-pad weight and leptin levels (Figures 6C–6E). The divergence
in body weight between the Pomc-Tsc1cKO and control animals
Cell Metabolism
Anabolic Action of mTOR in Pomc NeuronsFigure 6. Ongoing Rapamycin Treatment Ameliorates the Hyperphagia and Obesity of Pomc-Tsc1cKO Mice
(A) Schema of two different cohort studies for (B)–(H) and Figure 7 using high-dose rapamycin (6 mg/kg body weight, i.p., every other day). For Treatment A,
Pomc-Tsc1cKO and WT mice were injected with rapamycin every other day (2–7 weeks) then injected with vehicle every other day (7–12 weeks). For Treatment
B, Pomc-Tsc1cKO and WT mice were injected with vehicle every other day (2–7 weeks) then injected with rapamycin every other day (7–12 weeks).
(B) Body weight in male littermates fed on regular chow diet from 2 to 12 weeks of age. Rapamycin ameliorated the obese phenotype in Pomc-Tsc1cKO mice.
Upper panel shows Treatment A (n = 6–10); lower panel, Treatment B (n = 7–10).
(C)Weightsof gonadal fatdeposits (percentage of bodyweight) from male mice at indicatedage (n = 6–10). Rapamycin normalized adiposity inPomc-Tsc1cKOmice.
(D) Serum leptin levels measured in ad lib-fed mice at indicated age (n = 6–10). Rapamycin attenuated hyperleptinemia in Pomc-Tsc1cKO mice.
(E) Comparison between weekly food intake in WT and Pomc-Tsc1cKO mice. Rapamycin improved hyperphagia in Pomc-Tsc1cKO mice. Data are average
weekly food intake from 4–7 or 7–12 weeks (n = 6–10). For (B)–(E), values are mean ± SEM. *p < 0.05; **p and ##p < 0.01. P-cKO or Pomc-cKO: Pomc-Tsc1cKO;
WT: control; Rap or Rapa: rapamycin; Veh: vehicle; Treat.: Treatment.ceased upon the initiation of rapamycin treatment at 7 weeks of
age, however, and food intake and measures of adiposity all
decreased toward control levels during the second (rapamycin)
phase of Treatment B (Figures 6B–6E). Interestingly, hypotha-
lamic Pomc mRNA expression did not vary by genotype, consis-
tent with the mainly nontranscriptional function of mTOR and
suggesting that the altered Pomc mRNA expression noted in
Rip-Tsc1cKO mice was likely due to indirect rather than cell-
autonomous effects of mTOR activation (Figure S5B). Similarly,blood glucose levels did not vary among groups, nor were there
differences in linear growth (as measured by snout-to-anus
length) between genotypes under any treatment conditions,
although this measure was slightly decreased by rapamycin treat-
ment in both genotypes (Figures S5C and S5D). Since genetic
interference with central melanocortin action generally promotes
increased linear growth, the normal body length of the Pomc-
Tsc1cKO mice suggests that cell-autonomous mTOR activation
interferes with other important aspects of Pomc neuron action.Cell Metabolism 9, 362–374, April 8, 2009 ª2009 Elsevier Inc. 369
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Anabolic Action of mTOR in Pomc NeuronsThus, the physiologic phenotypes of animals subjected to
Treatment A and Treatment B suggest an important role for
ongoing mTOR activation (as opposed to mTOR-mediated alter-
ations in development) in the hyperphagia and obesity of Pomc-
Tsc1cKO mice, sincemTORblockade normalizes the metabolism
of adult as well as younger animals and since these changes are
reversed when mTOR inhibition ceases.
Rapamycin Normalizes Neuronal Morphology
in Pomc-Tsc1cKO Mice
In order to examine the potential alteration of Pomc neurons with
mTOR activation and rapamycin-mediated inhibition, we exam-
ined thesize of Pomcneurons and thedensityof Pomc projections
to the PVN by ACTH immunofluorescence in 7 and 12-week-old
animals subjected to Treatment A and Treatment B. While rapa-
mycin treatment from 2 to 7 weeks of Treatment A normalized
the size of Pomc soma and the density of PVN projections in the
Pomc-Tsc1cKO mice at 7 weeks of age (Figures 7A and 7B), the
size of these neurons increased and their projection density
decreased over the subsequent 5 weeks of vehicle treatment
(Figures 7A and 7B). While the size of Pomc neurons in vehicle-
treatedPomc-Tsc1cKO mice was increased and PVN projections
were decreased relative to controls at 7 weeks of age (Figures 7A
and 7B), rapamycin administration to these animals from 7 to
12 weeks significantly reduced their Pomc somatic size and
partially improved the detection of ACTH-IR PVN projections in
Treatment B (Figures 7A and 7B). Thus, the increased size of
Pomc neurons and their decreased projection density to the
PVN in Pomc-Tsc1cKO mice is preventable by mTOR inhibition
in young animals but reverts upon the cessation of treatment.
While the alterations in Pomc somatic size remain largely revers-
ible by mTOR inhibition in older animals, rapamycin administration
to these adult animals does not completely restore ACTH-IR PVN
projections, suggesting roles for mTOR activity both in the devel-
opment and in the ongoing regulation of these projections. In
contrast, the ongoing levels of mTOR activity, not developmental
processes, largely determine the somatic size of Pomc neurons
and metabolic parameters in Pomc-Tsc1cKO mice.
DISCUSSION
The data presented here suggest that the hyperphagic and obese
phenotype ofRip-Tsc1cKO mice likely results from the ablation of
Tsc1 in the hypothalamus. Indeed, the b cell-specific (without
hypothalamic involvement) knockout of Tsc2 caused hyperinsu-
linemia but not obesity (Shigeyama et al., 2008). Furthermore,
treatment of mice with low-dose rapamycin (1 mg/kg body
weight), which blocks b cell hypertrophy and hyperinsulinemia
but does not normalize hypothalamic pS6-IR, does not prevent
the hyperphagia and obesity of the Rip-Tsc1cKO mice (our
unpublished data).
Deletion of Tsc1 specifically from Pomc-expressing cells
results in hyperphagia and obesity in Pomc-Tsc1cKO mice, and
this phenotype cannot be attributed to alterations in the function
of pituitary corticotrophs. Thus, these data suggest that constitu-
tive activation of mTOR in anorexigenic neurons of the hypothal-
amus dysregulates these neurons and results in hyperphagic
obesity. These neurons respond to a variety of signals, including
leptin and nutrients, to decrease feeding. A variety of data also370 Cell Metabolism 9, 362–374, April 8, 2009 ª2009 Elsevier Inc.suggest an important role for the insulin signaling cascade
(including PI3K) in the regulation of neuronal activity and metab-
olism (Belgardt et al., 2008; Choudhury et al., 2005; Kubota et al.,
2004; Lin et al., 2004; Plum et al., 2006). While the activation of
mTOR in peripheral tissues interferes with insulin/PI3K signaling,
we were not able to detect alterations in PI3K signaling in the
Pomc-Tsc1cKO mice (data not shown). The anorectic response
to central insulin is modest, and most inactivating mutations
in insulin signaling molecules (e.g., Insulin Receptor, PI3K, IRS-
proteins, etc.) in POMC neurons produce little change in overall
energy balance (Hill et al., 2008; Choudhury et al., 2005; Belgardt
et al., 2008; Konner et al., 2007). These findings, along with the
dramatic obesity of the Pomc-Tsc1cKO animals, suggest that
a direct effect of mTOR activation, rather than interference with
PI3K, underlies the obesity of Pomc-Tsc1cKO mice.
Increased mTOR activity cell-autonomously increases the
somatic size of Pomc neurons, consistent with the hypertrophic
effects of mTOR in other tissues (Meikle et al., 2008; Rachdi
et al., 2008; Shigeyama et al., 2008). Increased cell-autonomous
mTOR activity also impairs the ACTH-IR projections from the
ARC Pomc neurons. mTOR activation appears to modulate the
detection of ACTH-IR PVN projections by developmental as
well as ongoing processes, since the normalization of projections
by rapamycin treatment during development is at least partially
reversed upon the cessation of treatment, and 5 weeks of treat-
ment in older animals does not completely normalize projections
in Pomc-Tsc1cKO mice. The detection of PVN projections by
neuropeptide staining necessarily reflects the expression and
axonal content of the neuropeptide, and our data thus reflect
the combination of ACTH-IR peptide content as well as the
density of axonal projections to the PVN.
Increased Pomc somatic size in Pomc-Tsc1cKO mice is not
developmentally programmed, but is modulated by ongoing
mTOR activity, as is the impaired catabolic action of the melano-
cortin system in these mice. These data reveal an important role
for the postdevelopmental activation of mTOR in Pomc neurons
for metabolic regulation. Note, however, that these data cannot
rule out the possibility of a more modest effect of mTOR-depen-
dent developmental alterations in the Pomc system on energy
homeostasis, but rather reveal the dominant effect of ongoing
mTOR activation in this model system. It is possible that the early
activation of mTOR in Pomc and other hypothalamic neurons
may alter their normal developmental program, as observed in
states of maternal obesity and diabetes. Indeed, ablation of
Tsc1 in most neurons using Synapsin-Cre mice (Syn-Tsc1cKO)
results in a variety of neuropathological abnormalities, including
ectopic and hypomyelinated projections that may result from
developmental abnormalities (Meikle et al., 2007).
In contrast to our present data demonstrating that long-term
activation of the TSC-mTOR pathway impairs the function of
anorectic Pomc neurons, Cota et al. showed that the acute phar-
macologic inhibition of mTOR throughout the hypothalamus
impairs appetite control, presumably at least in part via the regu-
lation of AgRP neurons (Cota et al., 2006). A number of differences
between these studies may underlie the distinct results obtained.
While the Cota study essentially examined the effect of intracere-
broventricular rapamycin in all hypothalamic (and presumably
other) neurons near the third cerebral ventricle, our study isolated
the effect of mTOR activation specifically in Pomc neurons.
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Anabolic Action of mTOR in Pomc NeuronsFigure 7. Ongoing Rapamycin Treatment Normalized the Morphological Alterations of Pomc-Tsc1cKO Mice
(A) Immunohistochemistry for ACTH in ARC of 7- (left panels) or 12- (right panels) week-old Pomc-Tsc1cKO and control mice during Treatments A and B.
Rapamycin normalized the cell size in both young and adult Pomc-Tsc1cKO mice. 3V: third ventricle. Right panel shows quantification of ATCH-positive cell
size in the ARC. Measurement was as in Figure 4D. n > 3 per genotype.
(B) Effect of rapamycin on density of PVN projections; ACTH staining of 7- (left panels) and 12- (right panels) week-old Pomc-Tsc1cKO and control mice following
either Treatment A or B. For projection density in the PVN, ACTH-stained slices in both genotypes were measured. Values are expressed relative to projection
density of control in each group. For graphs in (A) and (B), values are mean ± SEM. *p < 0.05; **p < 0.01. P-cKO or Pomc-cKO: Pomc-Tsc1cKO; WT: control; Rap
or Rapa: rapamycin; Veh: vehicle; Treat.: Treatment.Cell Metabolism 9, 362–374, April 8, 2009 ª2009 Elsevier Inc. 371
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Anabolic Action of mTOR in Pomc NeuronsFurthermore, as our unpublished data reveal that neuronal activity
cell-autonomously regulates mTOR signaling in hypothalamic
neurons (E.C.V. and M.G.M., unpublished data), the function of
hypothalamic mTOR in the ultimate regulation of appetite should
depend upon the specific regulation and role of mTOR activity in
each neural subtype. As importantly, our examination of a system
with chronic activation of mTOR signaling contrasts with the
acute mTOR inhibition strategy utilized by Cota, et al. Thus, in our
genetic model, the chronic activation of mTOR in anorexigenic
hypothalamic neurons may mimic the effects observed in the
peripheral tissues of patients and animal models with obesity
and type 2 diabetes.
Our study indicates that uncontrolled mTOR activity impairs
the development of neuronal projections in a cell-autonomous
manner. In contrast, the main effects of mTOR activation in
Pomc neurons on somatic size and energy balance are revers-
ible, and chronic ongoing activation of mTOR in the hypotha-
lamic Pomc neurons, such as might be caused by overnutrition,
promotes the development of hyperphagic obesity. Such dysre-
gulation may promote hypothalamic dysfunction and further
overeating in states of overnutrition and obesity.
EXPERIMENTAL PROCEDURES
Animals and Animal Care
Tsc1lox/lox mice with exons 17 and 18 of Tsc1 flanked by loxP sites by homolo-
gous recombination have been described (Meikle et al., 2005; Uhlmann et al.,
2002). We generated b cell- and hypothalamic-specific Tsc1 knockout mice
(Rip-Tsc1cKO) by breeding Tsc1lox/lox mice with mice that express the Cre
recombinase gene under the control of the rat insulin 2 gene promoter (Jackson
Laboratory). Mice were maintained on the segregating (C57Bl/6;129Sv;BALB/c)
genetic background. We performed experiments using Rip-Cre/Tsc1lox/lox
Rip-Tsc1cKO) mice and Tsc1lox/lox littermates as controls (WT). Pomc-Cre
mice (FVB background) from Jackson Laboratory were mated with Tsc1lox/lox
mice to generate Pomc-Tsc1cKO same as Rip-Tsc1cKO and were maintained
on mixed genetic background. Mice were housed on a 12 hr light/dark cycle in
the Unit for Laboratory Animal Medicine (ULAM) at the University of Michigan,
with free access to water and standard mouse chow. Animal experiments
were conducted following protocols approved by the University Committee on
the Use and Care of Animals (UCUCA).
In Vivo Physiological Studies
Blood glucose levelswere determined using anautomated blood glucose reader
(Accu-Chek; Roche). Serum insulin and leptin levels were measured by ELISA
(Crystal Chem; Downers Grove, IL). For a leptin administration study, mice
were individually caged. Murine leptin (PeproTech; Rocky Hill, NJ) (2.5 mg/kg
body weight) was injected i.p. twice daily (at 9:00 and 18:00) for 2 days. Body
weight and food intake were measured daily before injection, during the treat-
ment period, and after a 2 day wash-out period following the injection. Serum
corticosterone levels were measured by Hormone Assay & Analytical Services
Core, MMPC, Vanderbilt University (NIH grant #DK59637).
Total body fat content was determined using a dual energy X-ray absorpti-
ometry (DEXA) scanner (GE Medical Systems Lunar) according to the manu-
facturer’s instructions.
Rapamycin Treatment Studies
Rapamycin (LC Laboratories; Woburn, MA) was initially dissolved in 100%
ethanol, stored at 20C, and further diluted in an aqueous solution of 5.2%
Tween 80 and 5.2% PEG 400 (final ethanol concentration, 2%) immediately
before use (Wendel et al., 2004). Rip-Tsc1cKO, Pomc-Tsc1cKO, and their
control animals were injected with rapamycin i.p. (6 mg/kg body weight, every
other day) for the periods shown in each experiment. Both pancreas and brain
tissues for western blotting, RT-PCR, and immunohistochemistry were har-
vested after 12 hr of the last treatment of rapamycin.372 Cell Metabolism 9, 362–374, April 8, 2009 ª2009 Elsevier Inc.Immunohistochemistry
Brains were harvested from both 24 hr fasted or ad libitum-fed mice at the
beginning of light cycle. After transcardiac perfusion with 4% paraformalde-
hyde, brains were postfixed in 4% paraformaldehyde and transferred to 20%
sucrose solution overnight. Tissues were frozen on dry ice, cut into 25 mm
coronal sections on a sliding microtome, collected in five series, and stored
in antifreeze solution (50% PBS, 15% ethyl glycol, and 35% glycerol) at
20C until further use. One series of brain sections was then stained with
Phospho-S6 (Ser235/236 [IHC preferred] or Alexa Fluor 488 Conjugated; Cell
Signaling Technology) and ACTH antibody (from Doctor Parwlow, National
Hormone and Peptide Program) using free-floating method.
Quantification of ACTH-Positive Cell Size in the ARC andProjections
to the PVN
For quantification of cell size in ACTH-positive cells in the ARC and projections
to the PVN, we used ImageJ software (NIH; Bethesda, MD). All high magnifica-
tion images were converted into binary files using a unique threshold value that
separated positively labeled cells from background. In order to exclude false
positives, the average size of cells that fell within a strict set of parameters
(larger than 0.2 mm2 and between 0.50 and 1.00 circularity) was quantified.
Average cell size of ACTH(+) cells within matched sections of the ARC were
compared. For projection density measurements in the PVN, ACTH(+)-stained
slices were converted into binary files to separate labeled projections from
background tissue. All images for intercomparison in this manner were
collected using identical microscope and camera settings on tissue samples
processed in parallel. Optical density measurements of projections within
a 2.0 3 2.0 circular selection area placed over the left side of each PVN
were compared.
Western Blot Analysis
Tissue extracts were immunoblotted with Tsc1, Tsc2, phospho-S6, S6 (Cell
Signaling), and a-tubulin (Sigma-Aldrich).
mRNA Quantification by RT-PCR Analysis
Hypothalami were harvested immediately from both 24 hr fasted and ad libitum-
fed mice at the beginning of light cycle and homogenized in Trizol reagent
(Invitrogen). Total RNA was isolated and used for reverse transcription by Super-
Script First-Strand Synthesis System (Invitrogen). Quantitative PCR was carried
out with specific primers. Leptin receptor (Lepr), Npy, Pomc, Agrp, and hypo-
xanthine phosphoribosyltransferase 1 (Hprt) mRNA levels were measured using
the ABI Prism 7300 Real-Time PCR System with SYBR green reagents (Applied
Biosystems, Inc.). The expression of each mRNA level was normalized to the
expression of Hprt. Primers for real-time RT-PCR were: Lepr sense, 50-GGG
TTTATCCATAGTCCTGTCA-30; Lepr antisense, 50-AAATGTCTGGGCCTCTG
TCTCC-30; Hprt sense, 50-TCATTATGCCGAGGATTTGGA-30; Hprt antisense,
50-GCACACAGAGGGCCACAAT-30. Primers for Pomc, Npy, and Agrp were
described previously (Bates et al., 2003).
Statistical Analyses
All data are presented as mean ± SEM and were analyzed by Student’s t test or
ANOVAs. The differences were considered to be significant if p < 0.05.
SUPPLEMENTAL DATA
Supplemental Data include five figures and can be found online at http://www.
cell.com/cellmetabolism/supplemental/S1550-4131(09)00065-5.
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